Clinical Trials Xpress, Named as a PAREXEL Strategic Site Alliance Network Member
Clinical Trials Xpress (CTX), an initiative of the University of Texas System, has been named by PAREXEL as a member of its Global Site Alliance Network. Within this network, CTX will work side-by-side with PAREXEL to promote more clinical development of drug therapies through research.
Read the full release here.
Key Phase 3 Trial Results Lead to FDA Approval of Fabhalta for Paroxysmal Nocturnal Hemoglobinuria
December 6th 2023Clinical trials demonstrated superiority of Fabhalta to anti-C5s in hemoglobin improvement in the absence of transfusions and transfusion avoidance rate, showing clinically meaningful hemoglobin-level increases without the need for blood transfusions in patients with paroxysmal nocturnal hemoglobinuria.
‘Hypothesis-Free’: Getting Proactive About Signal Detection
December 5th 2023Elizabeth Smalley, director of product management, data, and analytics at ArisGlobal speaks about her work at the software company in supporting the efforts of life sciences clinical and pharmacovigilance teams in signal detection.
